Post by PressReleaseon Sep 18, 2023 7:32am
62 Views
Post# 35640882
New Press Release - FSD Pharma announces Interim Results from First-in-Human Clinical Trial of Lucid-MS (Lucid-21-302) for Multiple Sclerosis; The Report Shows Compound to be Safe and Well Tolerated